GERON CORP — Form 8-K

Geron discontinued the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis based on an independent Data Monitoring Committee recommendation that the trial was unlikely to meet its primary overall survival endpoint. The trial enrolled 327 patients in a 2:1 randomized design comparing imetelstat (9.4 mg/kg IV every 3 weeks) to best available therapy. No new safety signals were identified. The company plans detailed data analysis and future scientific publication while focusing on growing RYTELO (imetelstat) demand in its approved lower-risk myelodysplastic syndrome indication.